Background: Symptoms of acute retroviral syndrome (ARS) in African adults differ by region and timing of ascertainment, with two Kenyan cohort studies that followed subjects monthly showing a higher report of symptoms and signs than a cohort study from Zambia that followed subjects every 3 months. We sought to determine whether reporting of ARS was associated with HIV-1 subtype at nine participating African research centres (CRC), representing countries with predominant HIV-1 subtypes A, C and D.
Methods: Adults with acute or early HIV-1 infection in a multicenter HIV-1 incidence study were enrolled in a sub-study assessing ARS. Estimated date of infection (EDI) was based on a positive plasma viral load or p24 antigen test prior to seroconversion, or the mid-point between a negative and positive HIV-1 serologic test. Eleven ARS signs and symptoms were assessed at sub-study enrollment. We used log-binomial regression to estimate the prevalence of ARS signs and symptoms ascertained in the period ≤ 42 days after EDI, by subtype, and sex.
Results: Among 155 volunteers ascertained within 6 weeks following EDI, 67 (43.2%) had pol-derived subtype A, 66 (42.6%) subtype C, and 22 (14.2%) subtype D infection. The number of men and gender ratio by subtype for subtype A was 45 (67%) men; for subtype C: 39 (59%) men, and for subtype D: 13 (59%) men. Individuals with subtype A were statistically significantly more likely than individuals with subtypes C and D to report any of the specifically-listed ARS symptoms, and among those reporting any symptoms (figure), the mean number of symptoms was significantly greater among those with subtype A than among those with subtype C or D. These associations were not modified by sex.
Conclusions: In this multicenter African cohort of patients evaluated within 6 weeks following EDI, individuals with subtype A were significantly more likely than individuals with subtypes C and D to report any of the 11 specifically-listed ARS symptoms. Further studies elucidating differences in innate immune responses by HIV-1 subtype in patients with acute HIV infections are recommended.